Incremental haemodialysis

Nephrology Dialysis Transplantation

Volumn 30, Issue 10, 2015, Pages 1639-1648

  Wong, Jonathan ^a,b   Vilar, Enric ^a,b   Davenport, Andrew ^c,d   Farrington, Ken ^a,b  

^a LISTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

haemodiafiltration; haemodialysis; hypotension; Kt V; residual renal function

Indexed keywords

BETA 2 MICROGLOBULIN; POLYSULFONE; UREA;

ARTICLE; BIOCOMPATIBILITY; BLOOD PRESSURE REGULATION; BLOOD VOLUME; COST CONTROL; END STAGE RENAL DISEASE; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCREMENTAL HEMODIALYSIS; KIDNEY FUNCTION; MEDICAL DECISION MAKING; OLIGURIA; PATIENT MONITORING; PATIENT SAFETY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL CLEARANCE; RESIDUAL KIDNEY FUNCTION; TREATMENT OUTCOME; KIDNEY FAILURE, CHRONIC; PROCEDURES; RENAL REPLACEMENT THERAPY; TIME FACTOR;

HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; RENAL DIALYSIS; TIME FACTORS;

EID: 84943402737     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv231     Document Type: Article

References (103)

1. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS) Kidney Int 1985; 28: 526-534
2. European Best Practice Guidelines. II.1 Haemodialysis dose quantification: small solutes. Nephrol Dial Transplant 2002; 17: 17-21
3. Clinical practice recommendations for peritoneal dialysis adequacy. Am J Kidney Dis 2006; 48(Suppl 1): S130-S158
4. European Best Practice Guidelines. II.3 Haemodialysis dose and residual renal function (Kr) Nephrol Dial Transplant 2002; 17: 24
5. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006; 48(Suppl 1): S2-90
6. Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 1998; 13(Suppl 6): 10-14
7. Ahmad S, Babb AL, Milutinovic J, et al. Effect of residual renal function on minimum dialysis requirements. Proc Eur Dial Transplant Assoc 1979; 16: 107-114
8. Bonomini V, Feletti C, Scolari MP, et al. Benefits of early initiation of dialysis. Kidney Int Suppl 1985; 17: S57-S59
9. NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation. Am J Kidney Dis 1997; 30(3 Suppl 2): S15-S66
10. Golper TA. Incremental dialysis. J Am Soc Nephrol 1998; 9(12 Suppl): S107-S111
11. Burkart JM, Golper TA. Should we treat patients with incremental dialysis prescriptions?. Blood Purif 2000; 18: 298-303
12. Lin Y-F, Huang J-W, Wu M-S, et al. Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis. Nephrology (Carlton) 2009; 14: 59-64
13. Kalantar-Zadeh K, Unruh M, Zager PG, et al. Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. Am J Kidney Dis 2014; 64: 181-186
14. Rhee CM, Unruh M, Chen J, et al. Infrequent dialysis: a new paradigm for hemodialysis initiation. Semin Dial 2013; 26: 720-727
15. Zhang M, Wang M, Li H, et al. Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. Am J Nephrol 2014; 40: 140-150
16. Teruel-Briones JL, Fernández-Lucas M, Rivera-Gorrin M, et al. Progression of residual renal function with an increase in dialysis: haemodialysis versus peritoneal dialysis. Nefrologia 2013; 33: 640-649
17. Vilar E, Wellsted D, Chandna SM, et al. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 2009; 24: 2502-2510
18. Daugirdas JT, Van Stone JC. Physiologic principles and urea kinetic modeling. In: Daugirdas JT, Blake PG, Ing TS (eds) Handbook of Dialysis. Philadelphia: Wolters Kluwer Health, 2015, pp. 34-65
19. Woodrow G, Davies S. Peritoneal Dialysis in chronic kidney disease. Solute Clearance (Guidelines 3.1-3.3) http://www.renal.org/guidelines/modules (16 May 2015, date last accessed
20. Depner TA. Hemodialysis adequacy: basic essentials and practical points for the nephrologist in training. Hemodial Int 2005; 9: 241-254
21. Daugirdas JT, Depner TA, Greene T, et al. Standard Kt/Vurea: a method of calculation that includes effects of fluid removal and residual kidney clearance. Kidney Int 2010; 77: 637-644
22. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
23. Casino FG, Lopez T. The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant 1996; 11: 1574-1581
24. Daugirdas JT, Tattersall J. Effect of treatment spacing and frequency on three measures of equivalent clearance, including standard Kt/V. Nephrol Dial Transplant 2010; 25: 558-561
25. Spalding EM, Chandna SM, Davenport A, et al. Kt/V underestimates the hemodialysis dose in women and small men. Kidney Int 2008; 74: 348-355
26. Barth RH. Urea modeling and Kt/V: a critical appraisal. Kidney Int Suppl 1993; 41: S252-S260
27. Basile C, Lomonte C. Kt/V urea does not tell it all. Nephrol Dial Transplant 2012; 27: 1284-1287
28. Himmelfarb J. Urea: surrogate or toxin?. Kidney Int 1999; 56: 754-755
29. Neirynck N, Vanholder R, Schepers E, et al. An update on uremic toxins. Int Urol Nephrol 2013; 45: 139-150
30. Sirich TL, Luo FJ-G, Plummer NS, et al. Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant 2012; 27: 1574-1579
31. Hosten A. BUN and creatinine. In: Walker H (eds) Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd Edn. Boston: Butterworths, 1990
32. Fürstenberg A, Davenport A. Comparison of multifrequency bioelectrical impedance analysis and dual-energy X-ray absorptiometry assessments in outpatient hemodialysis patients. Am J Kidney Dis 2011; 57: 123-129
33. Hanson JA, Hulbert-Shearon TE, Ojo AO, et al. Prescription of twiceweekly hemodialysis in the USA. Am J Nephrol 1999; 19: 625-633
34. Lin X, Yan Y, Ni Z, et al. Clinical outcome of twice-weekly hemodialysis patients in Shanghai. Blood Purif 2012; 33: 66-72
35. Bieber B, Qian J, Anand S, et al. Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and Quality of Life in the China Dialysis Outcomes and Practice Patterns study. Nephrol Dial Transplant 2014; 29: 1770-1777
36. McKane W, Chandna SM, Tattersall JE, et al. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 2002; 61: 256-265
37. Nongnuch A, Assanatham M, Panorchan K, et al. Strategies for preserving residual renal function in peritoneal dialysis patients. Clinical Kidney J 2015; 8: 202-211
38. Smith HW, Goldring W, Chasis H. The measurement of the tublar excretory mass, effective blood flow and filtration rate in the normal human kidney. J Clin Invest 1938; 17: 263-278
39. Rahn KH, Heidenreich S, Brückner D. How to assess glomerular function and damage in humans. J Hypertens 1999; 17: 309-317
40. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009; 20: 2305-2313
41. Swan SK, Halstenson CE, Kasiske BL, et al. Determination of residual renal function with iohexol clearance in hemodialysis patients. Kidney Int 1996; 49: 232-235
42. Van Olden RW, van Acker BA, Koomen GC, et al. Time course of inulin and creatinine clearance in the interval between two haemodialysis treatments. Nephrol Dial Transplant 1995; 10: 2274-2280
43. Milutinovic J, Cutler RE, Hoover P, et al. Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis. Kidney Int 1975; 8: 185-190
44. Davenport A, Cholongitas E, Xirouchakis E, et al. Pitfalls in assessing renal function in patients with cirrhosis-potential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant 2011; 26: 2735-2742
45. Bhavsar N, Appel L, Kusek J, et al. Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis 2012; 59: 653-662
46. Filler G, Priem F, Lepage N. ß-trace protein, cystatin C, ß2-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem 2002; 48: 729-736
47. Filler G, Bokenkamp A, Hofmann W. Cystatin C as a marker of GFR -history, indications and future research. Clin Biochem 2005; 38: 1-8
48. Eguchi Y, Eguchi N, Oda H, et al. Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci USA 1997; 94: 14689-14694
49. Fry AC, Singh DK, Chandna SM, et al. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in highflux haemodialysis and on-line haemodiafiltration. Blood Purif 2007; 25: 295-302
50. Penne EL, van Der Weerd NC, Blankestijn PJ, et al. Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. Clin J Am Soc Nephrol 2010; 5: 80-86
51. Oates T, Pinney JH, Davenport A. Haemodiafiltration versus high flux haemodialysis: effects on phosphate control and erythropoietin response. Am J Nephrol 2011; 33: 70-75
52. Vilar E, Boltiador C, Viljoen A, et al. Removal and rebound kinetics of cystatin C in high-flux hemodialysis and hemodiafiltration. Clin J Am Soc Nephrol 2014; 9: 1240-1247
53. Bammens B, Evenepoel P, Verbeke K, et al. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64: 2238-2243
54. Marquez IO, Tambra S, Luo FY, et al. Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol 2011; 6: 290-296
55. Masereeuw R, Mutsaers HAM, Toyohara T, et al. The kidney and uremic toxin removal: glomerulus or tubule?. Semin Nephrol 2014; 34: 191-208
56. Vilar E, Farrington K. Emerging importance of residual renal function in end-stage renal failure. Semin Dial 2011; 24: 487-494
57. Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564
58. Amici G, Virga G, Da Rin G, et al. Serum beta-2-microglobulin level and residual renal function in peritoneal dialysis. Nephron 1993; 65: 469-471
59. Penne E, van Der Weerd N, Grooteman M. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 281-289
60. Menon MK, Naimark DM, Bargman JM, et al. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001; 16: 2207-2213
61. Wang AY, Sea MM, Ip R, et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001; 12: 2450-2457
62. Wang AY-M, Woo J, Wang M, et al. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 2005; 20: 396-403
63. Chandna SM, Farrington K. Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial 2004; 17: 196-201
64. Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997; 30: 366-373
65. McCarthy JT, Jenson BM, Squillace DP, et al. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis 1997; 29: 576-583
66. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17: 1814-1818
67. Jansen MAM, Hart AAM, Korevaar JC, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-1053
68. Burton JO, Jefferies HJ, Selby NM, et al. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009; 4: 1925-1931
69. Patel N, Hu SL. Preserving residual renal function in dialysis: what we know. Semin Dial 2015; 28: 250-258
70. Hall YN, Larive B, Painter P, et al. Effects of six versus three times per week hemodialysis on physical performance, health, and functioning: Frequent Hemodialysis Network (FHN) randomized trials. Clin J Am Soc Nephrol 2012; 7: 782-794
71. Chan CT, Greene T, Chertow GM, et al. Effects of frequent hemodialysis on ventricular volumes and left ventricular remodeling. Clin J Am Soc Nephrol 2013; 8: 2106-2116
72. Kalantar-Zadeh K, Casino FG. Let us give twice-weekly hemodialysis a chance: revisiting the taboo. Nephrol Dial Transplant 2014; 29: 1618-1620
73. Canaud B, Lertdumrongluk P. Probing "dry weight' in haemodialysis patients: "back to the future'. Nephrol Dial Transplant 2012; 27: 2140-2143
74. Charra B, Bergström J, Scribner BH. Blood pressure control in dialysis patients: importance of the lag phenomenon. Am J Kidney Dis 1998; 32: 720-724
75. Agarwal R, Alborzi P, Satyan S, et al. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009; 53: 500-507
76. Gunal AI, Kirciman E, Guler M, et al. Should the preservation of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients?. Ren Fail 2004; 26: 405-409
77. McCafferty K, Fan S, Davenport A. Extracellular volume expansion, measured by multifrequency bioimpedance, does not help preserve residual renal function in peritoneal dialysis patients. Kidney Int 2014; 85: 151-157
78. Weir MR. Hypervolemia and blood pressure: powerful indicators of increased mortality among hemodialysis patients. Hypertension 2010; 56: 341-343
79. Fan S, Sayed RH, Davenport A. Extracellular volume expansion in peritoneal dialysis patients. Int J Artif Organs 2012; 35: 338-345
80. Davenport A, Sayed RH, Fan S. Is extracellular volume expansion of peritoneal dialysis patients associated with greater urine output?. Blood Purif 2011; 32: 226-231
81. Hur E, Usta M, Toz H, et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis 2013; 61: 957-965
82. Onofriescu M, Hogas S, Voroneanu L, et al. Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial. Am J Kidney Dis 2014; 64: 111-118
83. Davies SJ, Davenport A. The role of bioimpedance and biomarkers in helping to aid clinical decision-making of volume assessments in dialysis patients. Kidney Int 2014; 86: 489-496
84. Chertow GM, Levin NW, Beck GJ, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363: 2287-2300
85. Unruh ML, Larive B, Chertow GM, et al. Effects of 6-times-weekly versus 3-times-weekly hemodialysis on depressive symptoms and self-reported mental health: Frequent Hemodialysis Network (FHN) Trials. Am J Kidney Dis 2013; 61: 748-758
86. Daugirdas JT, Greene T, Rocco MV, et al. Effect of frequent hemodialysis on residual kidney function. Kidney Int 2013; 83: 949-958
87. Rocco MV, Lockridge RS, Beck GJ, et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 2011; 80: 1080-1091
88. Farrington K. Commentary for "effect of frequent hemodialysis on residual kidney function': Frequent Hemodialysis Network (FHN) Trials. Kidney Int 2013; 83: 787-789
89. Lysaght MJ, Vonesh EF, Gotch F, et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37: 598-604
90. Supasyndh O, Satirapoj B, Seenamnogoen S, et al. Nutritional status of twice and thrice-weekly hemodialysis patients with weekly Kt/V > 3.6. J Med Assoc Thai 2009; 92: 624-631
91. Vanholder R, Van Biesen W, Lameire N. Is starting hemodialysis on a twice-weekly regimen a valid option?. Am J Kidney Dis 2014; 64: 165-167
92. Parisotto MT, Schoder VU, Miriunis C, et al. Cannulation technique influences arteriovenous fistula and graft survival. Kidney Int 2014; 86: 790-797
93. Ito S, Yoshida M. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Toxins (Basel) 2014; 6: 665-678
94. Vanholder R, Van Laecke S, Glorieux G. What is new in uremic toxicity?. Pediatr Nephrol 2008; 23: 1211-1221
95. Tattersall J. Clearance of beta-2-microglobulin and middle molecules in haemodiafiltration. Contrib Nephrol 2007; 158: 201-209
96. Foley RN, Gilbertson DT, Murray T, et al. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011; 365: 1099-1107
97. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 2011; 79: 250-257
98. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69: 1222-1228
99. Ruhi Ç, Koçak H, Yavuz A, et al. Use of peritoneal ultrafiltration in the elderly refractory congestive heart failure patients. Int Urol Nephrol 2012; 44: 963-969
100. Kumar S, Khosravi M, Massart A, et al. Changes in upper limb extracellular water content during hemodialysis measured by multi-frequency bioimpedance. Int J Artif Organs 2013; 36: 203-207
101. Booth J, Pinney J, Davenport A. Do changes in relative blood volume monitoring correlate to hemodialysis-associated hypotension?. Nephron Clin Pract 2011; 117: c179-c183
102. Booth J, Pinney J, Davenport A. N-terminal proBNP-marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients?. Clin J Am Soc Nephrol 2010; 5: 1036-1040
103. Davenport A. Changes in N-terminal pro-brain natriuretic peptide correlate with fluid volume changes assessed by bioimpedance in peritoneal dialysis patients. Am J Nephrol 2012; 36: 371-376